Abstract
Recently, new broad spectrum carbapenem has been investigated on a world-wide scale for the treatment of moderate to severe infections. In the neonatal intensive care units the extensive use of third generation cephalosporins for therapy of neonatal sepsis may lead to rapid emergence of multiresistant gram-negative organisms. We report the use of meropenem in 35 infants with severe infections due toAcinetobacter baumanii andKlebsiella pneumoniae. All gram negative bacteria were resistant to ampicillin, amoxicillin, ticarcilin, cefazoline, cefotaxime, ceftazidime, ceftriaxone and aminoglycosides. Eighty two percent of the cases (29/35) were born prematurely. Assisted ventilation was needed in 85.7 % (30/35). All infants deteriorated during their conventional treatment and were changed to meropenem monotherapy. Six percent (2/35) died. The incidence of drug-related adverse events (mostly a slight increase in liver enzymes) was 8.5 %. No adverse effects such as diarrhea, vomiting, rash, glossitis, oral or diaper area moniliasis, thrombocytosis, thrombocytopenia, eosinophilia and seizures were observed. At the end of therapy, overall satisfactory clinical and bacterial response was obtained in 33/35 (94.3%) of the newboms treated with meropenem. Clinical and bacterial response rates for meropenem were 100% for sepsis and 87.5% for nosocomial pneumonia. This report suggests that meropenem may be a useful antimicrobial agent in neonatal infections caused by multiresistant gram negative bacilli. Further studies are needed to confirm these results : Meropenem, newborn, sepsis and nosocomial infection.
Similar content being viewed by others
References
Hemming VG, Overall JC Jr, Britt MR. Nosocomial infections in a newborn’intensive-care unit. Results of forty-one months of surveillance.N Eng J Med 1976; 294: 1310–1316.
Welliver RC, McLaughlin S. Unique epidemiology of nosocomial infection in a children’s hospital.Am J Dis Child 1984; 138: 131–135.
Bennet R, Bergdahl S, Eriksson M, Zetterstrom R. The outcome of neonatal septicemia during fifteen years.Ada Paediatr Scand 1989; 78: 40–43.
Bryan CS, John JF Jr, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance.Am J Dis Child 1985; 139: 1086–1089.
Adam D: Challenges in the management of serious infections in pediatric patients.Fed Infect Dis 1996; 15 : 729–732.
Bradley JS, Faulkner KL, Klugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients.Pediatr Infect Dis J 1996; 15: 749–757.
Blumer JL. Meropenem: evaluation of a new generation carbapenem.International Journal of Antimicrobial Agents, 1997; 8(2): 73–92.
Freji BJ McCracken GH. Acute infections. In Avery GB, Fletcher MA, MacDonald MG, eds.Neonatology. Pathophysiology and management of the newborn (4 th ed). Philadelphia; J. B. Lippincott Company; 1994: 1082–1116.
Shay DK, Jarvis WR. Infections associated with hospitalizations. In Long SS, Pickering LK, Prober CG, (eds)Pediatric Infectious Diseases New York; Churchill Livingstone 1997: 656–684.
St.Geme IIIJW, Polin RA. Prevention and treatment of neonatal sepsis. In Spitzer AR (ed)Intensive Care of Fetus and Neonate (Chapter 76). St Louis: Mosby-Year Book, 1996.
Principi N, Marchisio P, Italian Pediatric Meropenem Study Group. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children.J Chemothrapy 1998; 10(2): 108–113.
Gaynes RP, Edwards JR, Jarvis WR, Culver DH, Tolson JS, Martone WJ. Nosocomial infections among neonates in high risk nurseries in the United States. National Nosocomial Infections Surveillance System.Pediatrics 1996; 98: 357–361.
Peter G, Cashore WJ; Infections acquired in the nursery: epidemiolgy and control. In Remington JS, Klein J, (eds),Infectious Diseases of the Fetus and Newborn Infant (3rd ed). Philadelphia; WB Saunders : 1990 : 1000–1019.
Drews MB, Ludwig AC, Leititis JU, Daschner FD. Low birth weight and nosocomial infection of neonates in a neonatal intensive care unit.J Hosp Infect 1995; 30: 65–72.
Flidel-Rimon O, Leibovitz E, Juster-Reicher A, Amitay M, Miskin A, Barak Yet al. An outbreak of antibiotic multiresistant Klebsiella at the Neonatal Intensive Care Unit, Kaplan Hospital, Rehovot, Israel, November 1991 to April 1992.Am J Perinatol 1996 ;13: 99–102.
Martinkova J, de Groot R, Chladek Jet al. Meropenem pharmacokinetics in pre-term and full-term neonates. Program and abstracts of the 7thEur Congr Clin Microbiol Infect Dis, Vienna, 1995; 133 abs 686.
Van den Anker J, Mouton J. The use of meropenem in neonatal invasive infections due to multiresistant gramnegative bacteria. Abstracts of the20th International Congress of Chemotherapy 1997; 211 Abs 5336.
Yatsyk GV. Use of meropenem in the treatment of severe infections in newborns.Antibiot Khimioter 1998; 43(1): 32–33.
Adam D. Carbapeneme bei padiatrischen infektionen.Chemotherapie J 1996; 5 suppl 9: 19–23.
Blumer JL, Reed MD, Kearns GLet al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.Antimicrob Agents Chemother 1995; 39: 1721–1725.
Klugman KP, Dagan R. Meropenem meningitis study group. Randomized treatment of bacterial meningitis.Antimicrob Agents Chemother 1995; 39: 1140–1146.
Schuler D. Safety and efficacy of meropenem in hospitalized children: randomized comparison with cefotaxime, alone and combined with metronidazole or amikacin.J Antimicrob Chemother 1995; 36 (suppl A): 99–108.
Lopez E, The Meropenem Study Group. Meropenem versus cefotaxime or ceftriaxone for bacterial meningitis. 33rdInterscience Conference on Antimicrobial Agents and Chemotherapy; New Orlean; 1995; 236 : abs 638.
Byrne S, Maddison J, Connoret al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.J Antimicrob Chemother 1995 ; 36 (suppl A): 135–143.
Bradley JS Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics.Fed Infect Dis J 1997; 16 : 263–268.
Topham JC, Murgatroyd LB, Jones DV, Goonetilleke UR, Wright J. Safety evaluation of meropenem in animals: studies on the kidney.J Antimicrob Chemother 1989; 24 (suppl A): 287–306.
Parker EM, Hutchison M, Blumer JL. The pharmacokinetics of meropenem in infants and children: A population analysis.J Antimicrob Chem 1995; 36 (suppl A): 63–71.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Köksal, N., Hacimustafaoğlu, M., Bağci, S. et al. Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. Indian J Pediatr 68, 15–19 (2001). https://doi.org/10.1007/BF02728850
Issue Date:
DOI: https://doi.org/10.1007/BF02728850